Research & Development
Researching New Therapeutic Approaches Against Infectious Diseases
AJK Biopharmaceutical has developed lead and backup drug candidates with broad-spectrum activity against Gram-positive and Gram-negative ESKAPE and resistant bacterial pathogens. Our proprietary candidates were designed to disrupt the bacterial membranes due to their amphipathic properties. The work is based on more than 15 years of focused academic research.
Antimicrobial Resistance (AMR) occurs when microbes change or mutate over time, making infections harder to treat for any given therapeutic agent. Our cyclic peptides appear to be resistant to changes in efficacy that are usually seen over time, as observed in serial passaging experiments with multiple strains of drug-resistant bacteria. The peptides have synergistic activity with antibiotics and inhibit the formation of bacterial biofilms.